Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.
The Boston, MA-based company was founded in 2024 and plans to list on the Nasdaq under the symbol SPTX. Seaport Therapeutics filed confidentially on November 21, 2025. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.